Compare Stocks

5 / 10
Try these comparisons:

Stock Comparison

LFWD vs MBOT vs ISRG vs NVCR vs SYK

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
LFWD
Lifeward Ltd.

Medical - Devices

HealthcareNASDAQ • IL
Market Cap$10M
5Y Perf.-93.9%
MBOT
Microbot Medical Inc.

Medical - Instruments & Supplies

HealthcareNASDAQ • US
Market Cap$143M
5Y Perf.-71.8%
ISRG
Intuitive Surgical, Inc.

Medical - Instruments & Supplies

HealthcareNASDAQ • US
Market Cap$159.85B
5Y Perf.+132.8%
NVCR
NovoCure Limited

Medical - Instruments & Supplies

HealthcareNASDAQ • JE
Market Cap$2.04B
5Y Perf.-73.5%
SYK
Stryker Corporation

Medical - Devices

HealthcareNYSE • US
Market Cap$109.33B
5Y Perf.+45.8%

LFWD vs MBOT vs ISRG vs NVCR vs SYK — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
LFWD logoLFWD
MBOT logoMBOT
ISRG logoISRG
NVCR logoNVCR
SYK logoSYK
IndustryMedical - DevicesMedical - Instruments & SuppliesMedical - Instruments & SuppliesMedical - Instruments & SuppliesMedical - Devices
Market Cap$10M$143M$159.85B$2.04B$109.33B
Revenue (TTM)$22M$0.00$10.58B$674M$25.12B
Net Income (TTM)$-20M$-13M$2.98B$-173M$3.25B
Gross Margin38.3%66.3%75.2%63.5%
Operating Margin-76.7%30.5%-27.2%22.4%
Forward P/E43.3x19.1x
Total Debt$2M$111K$303M$290M$14.86B
Cash & Equiv.$2M$3M$3.37B$103M$4.01B

LFWD vs MBOT vs ISRG vs NVCR vs SYKLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

LFWD
MBOT
ISRG
NVCR
SYK
StockMay 20May 26Return
Lifeward Ltd. (LFWD)1006.1-93.9%
Microbot Medical In… (MBOT)10028.2-71.8%
Intuitive Surgical,… (ISRG)100232.8+132.8%
NovoCure Limited (NVCR)10026.5-73.5%
Stryker Corporation (SYK)100145.8+45.8%

Price return only. Dividends and distributions are not included.

Quick Verdict: LFWD vs MBOT vs ISRG vs NVCR vs SYK

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: ISRG and SYK are tied at the top with 3 categories each (5-stock set) — the right choice depends on your priorities. Stryker Corporation is the stronger pick specifically for valuation and capital efficiency and capital preservation and lower volatility. NVCR also leads in specific categories worth noting. As sector peers, any of these can serve as alternatives in the same allocation.
LFWD
Lifeward Ltd.
The Healthcare Pick

LFWD lags the leaders in this set but could rank higher in a more targeted comparison.

Best for: healthcare exposure
MBOT
Microbot Medical Inc.
The Healthcare Pick

Among these 5 stocks, MBOT doesn't own a clear edge in any measured category.

Best for: healthcare exposure
ISRG
Intuitive Surgical, Inc.
The Growth Play

ISRG carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.

  • Rev growth 20.5%, EPS growth 22.6%, 3Y rev CAGR 17.4%
  • 5.5% 10Y total return vs SYK's 179.2%
  • Lower volatility, beta 1.00, Low D/E 1.7%, current ratio 4.87x
  • Beta 1.00, current ratio 4.87x
Best for: growth exposure and long-term compounding
NVCR
NovoCure Limited
The Momentum Pick

NVCR ranks third and is worth considering specifically for momentum.

  • +2.6% vs LFWD's -60.4%
Best for: momentum
SYK
Stryker Corporation
The Income Pick

SYK is the #2 pick in this set and the best alternative if income & stability and valuation efficiency is your priority.

  • Dividend streak 34 yrs, beta 0.52, yield 1.2%
  • PEG 1.28 vs ISRG's 1.99
  • Better valuation composite
  • Beta 0.52 vs NVCR's 2.15, lower leverage
Best for: income & stability and valuation efficiency
See the full category breakdown
CategoryWinnerWhy
GrowthISRG logoISRG20.5% revenue growth vs MBOT's -17.1%
ValueSYK logoSYKBetter valuation composite
Quality / MarginsISRG logoISRG28.2% margin vs LFWD's -90.4%
Stability / SafetySYK logoSYKBeta 0.52 vs NVCR's 2.15, lower leverage
DividendsSYK logoSYK1.2% yield; 34-year raise streak; the other 4 pay no meaningful dividend
Momentum (1Y)NVCR logoNVCR+2.6% vs LFWD's -60.4%
Efficiency (ROA)ISRG logoISRG14.8% ROA vs LFWD's -78.4%, ROIC 15.0% vs -122.9%

LFWD vs MBOT vs ISRG vs NVCR vs SYK — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

LFWDLifeward Ltd.
FY 2025
Product
100.0%$17M
MBOTMicrobot Medical Inc.

Segment breakdown not available.

ISRGIntuitive Surgical, Inc.
FY 2025
Instruments and Accessories
59.8%$6.0B
Systems
24.6%$2.5B
Services
15.6%$1.6B
NVCRNovoCure Limited

Segment breakdown not available.

SYKStryker Corporation
FY 2025
MedSurg
62.3%$15.6B
Orthopaedics
37.7%$9.5B

LFWD vs MBOT vs ISRG vs NVCR vs SYK — Financial Metrics

Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLISRGLAGGINGNVCR

Income & Cash Flow (Last 12 Months)

ISRG leads this category, winning 4 of 6 comparable metrics.

SYK and MBOT operate at a comparable scale, with $25.1B and $0 in trailing revenue. ISRG is the more profitable business, keeping 28.2% of every revenue dollar as net income compared to LFWD's -90.4%. On growth, ISRG holds the edge at +23.0% YoY revenue growth, suggesting stronger near-term business momentum.

MetricLFWD logoLFWDLifeward Ltd.MBOT logoMBOTMicrobot Medical …ISRG logoISRGIntuitive Surgica…NVCR logoNVCRNovoCure LimitedSYK logoSYKStryker Corporati…
RevenueTrailing 12 months$22M$0$10.6B$674M$25.1B
EBITDAEarnings before interest/tax-$17M-$14M$3.8B-$165M$6.3B
Net IncomeAfter-tax profit-$20M-$13M$3.0B-$173M$3.2B
Free Cash FlowCash after capex-$17M-$11M$2.8B-$48M$4.3B
Gross MarginGross profit ÷ Revenue+38.3%+66.3%+75.2%+63.5%
Operating MarginEBIT ÷ Revenue-76.7%+30.5%-27.2%+22.4%
Net MarginNet income ÷ Revenue-90.4%+28.2%-25.7%+12.9%
FCF MarginFCF ÷ Revenue-76.4%+26.8%-7.1%+17.1%
Rev. Growth (YoY)Latest quarter vs prior year-32.7%+23.0%+12.3%+11.4%
EPS Growth (YoY)Latest quarter vs prior year+82.7%+62.8%+18.8%-100.0%+56.0%
ISRG leads this category, winning 4 of 6 comparable metrics.

Valuation Metrics

SYK leads this category, winning 5 of 7 comparable metrics.

At 34.0x trailing earnings, SYK trades at a 41% valuation discount to ISRG's 57.2x P/E. Adjusting for growth (PEG ratio), SYK offers better value at 2.29x vs ISRG's 2.63x — a lower PEG means you pay less per unit of expected earnings growth.

MetricLFWD logoLFWDLifeward Ltd.MBOT logoMBOTMicrobot Medical …ISRG logoISRGIntuitive Surgica…NVCR logoNVCRNovoCure LimitedSYK logoSYKStryker Corporati…
Market CapShares × price$10M$143M$159.8B$2.0B$109.3B
Enterprise ValueMkt cap + debt − cash$9M$140M$156.8B$2.2B$120.2B
Trailing P/EPrice ÷ TTM EPS-0.38x-2.92x57.19x-14.66x33.98x
Forward P/EPrice ÷ next-FY EPS est.43.35x19.06x
PEG RatioP/E ÷ EPS growth rate2.63x2.29x
EV / EBITDAEnterprise value multiple43.28x19.76x
Price / SalesMarket cap ÷ Revenue0.45x15.88x3.11x4.35x
Price / BookPrice ÷ Book value/share8.99x9.44x9.10x5.86x4.87x
Price / FCFMarket cap ÷ FCF64.18x25.53x
SYK leads this category, winning 5 of 7 comparable metrics.

Profitability & Efficiency

ISRG leads this category, winning 7 of 9 comparable metrics.

ISRG delivers a 16.9% return on equity — every $100 of shareholder capital generates $17 in annual profit, vs $-146 for LFWD. ISRG carries lower financial leverage with a 0.02x debt-to-equity ratio, signaling a more conservative balance sheet compared to NVCR's 0.85x. On the Piotroski fundamental quality scale (0–9), ISRG scores 6/9 vs MBOT's 3/9, reflecting solid financial health.

MetricLFWD logoLFWDLifeward Ltd.MBOT logoMBOTMicrobot Medical …ISRG logoISRGIntuitive Surgica…NVCR logoNVCRNovoCure LimitedSYK logoSYKStryker Corporati…
ROE (TTM)Return on equity-145.5%-37.1%+16.9%-50.8%+15.0%
ROA (TTM)Return on assets-78.4%-34.4%+14.8%-16.5%+6.9%
ROICReturn on invested capital-122.9%-6.2%+15.0%-16.4%+11.4%
ROCEReturn on capital employed-108.5%-2.9%+16.5%-28.9%+13.0%
Piotroski ScoreFundamental quality 0–933656
Debt / EquityFinancial leverage0.19x0.03x0.02x0.85x0.66x
Net DebtTotal debt minus cash-$585,000-$3M-$3.1B$187M$10.8B
Cash & Equiv.Liquid assets$2M$3M$3.4B$103M$4.0B
Total DebtShort + long-term debt$2M$111,000$303M$290M$14.9B
Interest CoverageEBIT ÷ Interest expense-41.85x-96.80x6.72x
ISRG leads this category, winning 7 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

Evenly matched — MBOT and ISRG and NVCR each lead in 2 of 6 comparable metrics.

A $10,000 investment in ISRG five years ago would be worth $16,174 today (with dividends reinvested), compared to $470 for LFWD. Over the past 12 months, NVCR leads with a +2.6% total return vs LFWD's -60.4%. The 3-year compound annual growth rate (CAGR) favors MBOT at 22.8% vs LFWD's -50.0% — a key indicator of consistent wealth creation.

MetricLFWD logoLFWDLifeward Ltd.MBOT logoMBOTMicrobot Medical …ISRG logoISRGIntuitive Surgica…NVCR logoNVCRNovoCure LimitedSYK logoSYKStryker Corporati…
YTD ReturnYear-to-date-13.0%+0.9%-19.9%+36.4%-17.8%
1-Year ReturnPast 12 months-60.4%-16.8%-16.4%+2.6%-24.5%
3-Year ReturnCumulative with dividends-87.5%+85.2%+48.5%-74.2%+2.4%
5-Year ReturnCumulative with dividends-95.3%-69.7%+61.7%-90.2%+17.5%
10-Year ReturnCumulative with dividends-100.0%-99.4%+549.2%+38.5%+179.2%
CAGR (3Y)Annualised 3-year return-50.0%+22.8%+14.1%-36.4%+0.8%
Evenly matched — MBOT and ISRG and NVCR each lead in 2 of 6 comparable metrics.

Risk & Volatility

Evenly matched — NVCR and SYK each lead in 1 of 2 comparable metrics.

SYK is the less volatile stock with a 0.52 beta — it tends to amplify market swings less than NVCR's 2.15 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. NVCR currently trades 89.2% from its 52-week high vs LFWD's 36.7% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricLFWD logoLFWDLifeward Ltd.MBOT logoMBOTMicrobot Medical …ISRG logoISRGIntuitive Surgica…NVCR logoNVCRNovoCure LimitedSYK logoSYKStryker Corporati…
Beta (5Y)Sensitivity to S&P 5001.22x1.90x1.00x2.15x0.52x
52-Week HighHighest price in past year$17.76$4.67$603.88$20.06$404.87
52-Week LowLowest price in past year$0.67$1.60$427.84$9.82$284.97
% of 52W HighCurrent price vs 52-week peak+36.7%+45.6%+74.5%+89.2%+70.5%
RSI (14)Momentum oscillator 0–10045.343.043.670.926.6
Avg Volume (50D)Average daily shares traded11K1.5M1.8M1.4M2.1M
Evenly matched — NVCR and SYK each lead in 1 of 2 comparable metrics.

Analyst Outlook

SYK leads this category, winning 1 of 1 comparable metric.

Analyst consensus: LFWD as "Buy", MBOT as "Buy", ISRG as "Buy", NVCR as "Buy", SYK as "Buy". Consensus price targets imply 158.2% upside for MBOT (target: $6) vs 36.5% for SYK (target: $390). SYK is the only dividend payer here at 1.18% yield — a key consideration for income-focused portfolios.

MetricLFWD logoLFWDLifeward Ltd.MBOT logoMBOTMicrobot Medical …ISRG logoISRGIntuitive Surgica…NVCR logoNVCRNovoCure LimitedSYK logoSYKStryker Corporati…
Analyst RatingConsensus buy/hold/sellBuyBuyBuyBuyBuy
Price TargetConsensus 12-month target$10.75$5.50$622.60$33.50$389.62
# AnalystsCovering analysts53551550
Dividend YieldAnnual dividend ÷ price+1.2%
Dividend StreakConsecutive years of raises034
Dividend / ShareAnnual DPS$3.36
Buyback YieldShare repurchases ÷ mkt cap0.0%0.0%+1.4%0.0%0.0%
SYK leads this category, winning 1 of 1 comparable metric.
Key Takeaway

ISRG leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). SYK leads in 2 (Valuation Metrics, Analyst Outlook). 2 tied.

Best OverallIntuitive Surgical, Inc. (ISRG)Leads 2 of 6 categories
Loading custom metrics...

LFWD vs MBOT vs ISRG vs NVCR vs SYK: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is LFWD or MBOT or ISRG or NVCR or SYK a better buy right now?

For growth investors, Intuitive Surgical, Inc.

(ISRG) is the stronger pick with 20. 5% revenue growth year-over-year, versus -14. 1% for Lifeward Ltd. (LFWD). Stryker Corporation (SYK) offers the better valuation at 34. 0x trailing P/E (19. 1x forward), making it the more compelling value choice. Analysts rate Lifeward Ltd. (LFWD) a "Buy" — based on 5 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — LFWD or MBOT or ISRG or NVCR or SYK?

On trailing P/E, Stryker Corporation (SYK) is the cheapest at 34.

0x versus Intuitive Surgical, Inc. at 57. 2x. On forward P/E, Stryker Corporation is actually cheaper at 19. 1x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Stryker Corporation wins at 1. 28x versus Intuitive Surgical, Inc. 's 1. 99x — a reasonable growth-adjusted valuation.

03

Which is the better long-term investment — LFWD or MBOT or ISRG or NVCR or SYK?

Over the past 5 years, Intuitive Surgical, Inc.

(ISRG) delivered a total return of +61. 7%, compared to -95. 3% for Lifeward Ltd. (LFWD). Over 10 years, the gap is even starker: ISRG returned +549. 2% versus LFWD's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — LFWD or MBOT or ISRG or NVCR or SYK?

By beta (market sensitivity over 5 years), Stryker Corporation (SYK) is the lower-risk stock at 0.

52β versus NovoCure Limited's 2. 15β — meaning NVCR is approximately 310% more volatile than SYK relative to the S&P 500. On balance sheet safety, Intuitive Surgical, Inc. (ISRG) carries a lower debt/equity ratio of 2% versus 85% for NovoCure Limited — giving it more financial flexibility in a downturn.

05

Which is growing faster — LFWD or MBOT or ISRG or NVCR or SYK?

By revenue growth (latest reported year), Intuitive Surgical, Inc.

(ISRG) is pulling ahead at 20. 5% versus -14. 1% for Lifeward Ltd. (LFWD). On earnings-per-share growth, the picture is similar: Lifeward Ltd. grew EPS 57. 1% year-over-year, compared to 8. 2% for Stryker Corporation. Over a 3-year CAGR, LFWD leads at 58. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — LFWD or MBOT or ISRG or NVCR or SYK?

Intuitive Surgical, Inc.

(ISRG) is the more profitable company, earning 28. 4% net margin versus -90. 4% for Lifeward Ltd. — meaning it keeps 28. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ISRG leads at 29. 3% versus -76. 7% for LFWD. At the gross margin level — before operating expenses — NVCR leads at 74. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is LFWD or MBOT or ISRG or NVCR or SYK more undervalued right now?

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Stryker Corporation (SYK) is the more undervalued stock at a PEG of 1. 28x versus Intuitive Surgical, Inc. 's 1. 99x. A PEG below 1. 5 suggests fair-to-attractive pricing relative to expected growth. On forward earnings alone, Stryker Corporation (SYK) trades at 19. 1x forward P/E versus 43. 3x for Intuitive Surgical, Inc. — 24. 3x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for MBOT: 158. 2% to $5. 50.

08

Which pays a better dividend — LFWD or MBOT or ISRG or NVCR or SYK?

In this comparison, SYK (1.

2% yield) pays a dividend. LFWD, MBOT, ISRG, NVCR do not pay a meaningful dividend and should not be held primarily for income.

09

Is LFWD or MBOT or ISRG or NVCR or SYK better for a retirement portfolio?

For long-horizon retirement investors, Stryker Corporation (SYK) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

52), 1. 2% yield, +179. 2% 10Y return). Microbot Medical Inc. (MBOT) carries a higher beta of 1. 90 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (SYK: +179. 2%, MBOT: -99. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between LFWD and MBOT and ISRG and NVCR and SYK?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: LFWD is a small-cap quality compounder stock; MBOT is a small-cap quality compounder stock; ISRG is a mid-cap high-growth stock; NVCR is a small-cap quality compounder stock; SYK is a mid-cap quality compounder stock. SYK pays a dividend while LFWD, MBOT, ISRG, NVCR do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.

Stocks Like

LFWD

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Gross Margin > 22%
Run This Screen
Stocks Like

MBOT

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
Run This Screen
Stocks Like

ISRG

High-Growth Quality Leader

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 11%
  • Net Margin > 16%
Run This Screen
Stocks Like

NVCR

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 6%
  • Gross Margin > 45%
Run This Screen
Stocks Like

SYK

Stable Dividend Mega-Cap

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Net Margin > 7%
Run This Screen

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.